Clinical trials: psoriasis
Psoriatic Arthritis
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis.
- Trial name
- NCT05715125
- Testing
- Dose A VTX958, Dose B VTX958
- Where
- 46 sites in United States, Bulgaria and 5 more
- Volunteers
- 205 people
- Sponsor
- Ventyx Biosciences, Inc
Psoriatic Arthritis
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
- Trial name
- NCT01111240
- Where
- 509 sites in Germany
- Volunteers
- 4,635 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Trial of CF101 to Treat Patients With Psoriasis
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
- Trial name
- NCT01265667
- Testing
- CF101
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 293 people
- Sponsor
- Can-Fite BioPharma
Moderate to Severe Psoriatic Arthritis
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2.
- Trial name
- NCT07801495
- Testing
- DDY391
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis
It's clearly known that lymphocyte activation in particular Th17 response, plays a major role in the development of plaque psoriasis.
- Trial name
- NCT04459780
- Testing
- Skin biopsies, Blood sample
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Psoriasis
A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on…
- Trial name
- NCT02322086
- Testing
- Topical Rose Bengal, 0.005%
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Provectus Pharmaceuticals
Psoriasis
A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis
GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR) gamma. The aim of this study is to evaluate the safety, tolerability, clinical effect, and systemic exposure potential of topically applied…
- Trial name
- NCT03004846
- Testing
- GSK2981278 ointment, Vehicle ointment
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)
This Phase 3 study (Study 310) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT02742441
- Testing
- 122-0551 Foam, Vehicle Foam
- Where
- 21 sites in United States
- Volunteers
- 409 people
- Sponsor
- Therapeutics, Inc.
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRIB (NCT02019602)
- Testing
- Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 37 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Psoriasis
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of…
- Trial name
- NCT06846710
- Testing
- HS-20118
- Where
- 9 sites in United States, New Zealand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293722
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,308 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)
This is a multicenter, multinational (12 centers planned, in Germany 9 centers and in France, the Netherlands and the United Kingdom (UK) 1 center in each country respectively), randomized, double-blinded, placebo-controlled…
- Trial name
- METOP (NCT02902861)
- Testing
- Methotrexate
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Prof. Kristian Reich
Pruritus, Psoriasis Vulgaris
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.
- Trial name
- NCT03322137
- Testing
- SNA-120, Vehicle
- Where
- 38 sites in United States
- Volunteers
- 208 people
- Sponsor
- Sienna Biopharmaceuticals
Psoriasis
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.
- Trial name
- NCT00688519
- Testing
- U0267, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 336 people
- Sponsor
- Stiefel, a GSK Company
Mild to Moderate Psoriasis
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
A randomized, assessor blind, parallel group, three arms, active and placebo controlled study with objective to demonstrate therapeutic non-inferiority of AKP02 cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/…
- Trial name
- AKVANO-AKP02 (NCT05249972)
- Testing
- AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO), Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
- Where
- India
- Volunteers
- 294 people
- Sponsor
- Lipidor AB
Plaque Psoriasis
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
- Trial name
- NCT02274792
- Testing
- Etanercept
- Where
- 45 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Amgen
Psoriasis
Study Evaluating Management of Patients With Moderate and Severe Psoriasis
This is an observational, naturalistic, multicenter, retrospective study to describe the therapeutic management of patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs in usual clinical…
- Trial name
- NCT00894777
- Testing
- Clinical record review
- Where
- Spain
- Volunteers
- 469 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Stable Plaque Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02445807
- Testing
- DFD06-Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 265 people
- Sponsor
- Promius Pharma, LLC
Plaque Psoriasis
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
- Trial name
- NCT02462083
- Testing
- IDP-118 Lotion
- Where
- 46 sites in United States
- Volunteers
- 555 people
- Sponsor
- Bausch Health Americas, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.